Oral THC/CBD spray provides neuropathic pain control in MS patients, with mild/moderate side effects
How to Cite
OrthoEvidence. Oral THC/CBD spray provides neuropathic pain control in MS patients, with mild/moderate side effects. ACE Report. 2018;7(9):17. Available from: https://myorthoevidene.com/AceReport/Report/10352
Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trialClin Ther. 2007 Sep;29(9):2068-79
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Sixty-six patients from the UK with multiple sclerosis (MS) were enrolled in an initial 5-week, placebo-controlled RCT investigating the use of an oral-mucosal THC/CBD spray (Sativex). This study is an uncontrolled, open-label extension of the initial RCT, where all patients completing the initial RCT (n=64) were eligible to continue on the THC/CBD oral spray, and followed for 2-years. Sixty-three...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE